Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 11/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.49 |
| ▸ | CD74 | P04233 | 1/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.49 |
| ▸ | RPTOR | Q8N122 | 4/20 | 0.45 |
| ▸ | MLST8 | Q9BVC4 | 4/20 | 0.45 |
| ▸ | TNIK | Q9UKE5 | 3/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.42 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29522322 | 1.00 | MTOR (0.58) | MTORPIK3CACD74MIFRPTOR | |
| SCHEMBL482116 | 0.83 | MEN1 (0.43) | TNIKMEN1ALDH1A1KMT2AROCK2 | |
| SCHEMBL20892260 | 0.82 | MTOR (0.54) | MTORCD74MIFTNIKFYN | |
| SCHEMBL138490 | 0.80 | MTOR (0.58) | MTORPIK3CACD74MIFRPTOR | |
| SCHEMBL29522354 | 0.80 | MTOR (0.58) | MTORPIK3CACD74MIFRPTOR | |
| SCHEMBL19956323 | 0.76 | MTOR (0.54) | MTORCD74MIFTNIKFYN | |
| SCHEMBL138866 | 0.73 | MTOR (0.63) | MTORPIK3CARPTORMLST8TNIK | |
| SCHEMBL29522121 | 0.73 | MTOR (0.63) | MTORPIK3CARPTORMLST8TNIK | |
| SCHEMBL20017654 | 0.71 | MTOR (0.47) | MTORPIK3CARPTORMLST8TNIK | |
| SCHEMBL29522599 | 0.71 | MTOR (0.42) | MTORPIK3CARPTORMLST8TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493472-B1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARM LLC (US) | 2016-12-07 | — | — | EP | claimed |
| US-8569494-B2 | Methods of synthesis and purification of heteroaryl compounds | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-10-29 | — | — | US | claimed |
| EP-2493472-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | Signal Pharmaceuticals, LLC (US) | 2012-09-05 | — | — | EP | claimed |
| EP-2078016-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2012-02-01 | — | — | EP | claimed |
| EP-2358718-A1 | MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY | Signal Pharmaceuticals, LLC (US) | 2011-08-24 | — | — | EP | claimed |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | claimed |
| WO-2011053518-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-05-05 | — | — | WO | claimed |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC | 2010-08-26 | — | — | US | claimed |
| WO-2010062571-A1 | MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-06-03 | — | — | WO | claimed |
| US-20230338370-A1 | Treatment of Cancer with TOR Kinase Inhibitors | SIGNAL PHARM LLC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338370-A1 | Treatment of Cancer with TOR Kinase Inhibitors | SIGNAL PHARM LLC (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3660020-B1 | PROCESS FOR THE SYNTHESIS OF MTOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3660020-B1 | PROCESS FOR THE SYNTHESIS OF MTOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230119470-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2010062571-A1 | MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010062571-A1 | MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-06-03 | — | — | WO | disclosed |
| EP-2090577-A2 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | Signal Pharmaceuticals LLC (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2078016-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | disclosed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119470-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 6/4885CD74 3902/4885 |
| US-20230338370-A1 | Treatment of Cancer with TOR Kinase Inhibitors | MTOR, TTK, BRCA1 | MTOR 1/4885PIK3CA 4/4885CD74 4596/4885 |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 10/4885CD74 3528/4885 |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | AGER, GPR119, REL | MTOR 595/4885PIK3CA 2787/4885CD74 3817/4885 |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, PHKG1, PHKG2 | MTOR 73/4885PIK3CA 221/4885CD74 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.